Skip to main content

bluebird bio, Inc.

BLUEDelisted Jun 2, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001293971

bluebird bio, Inc. was delisted on Jun 2, 2025; its insiders filed their last Form 4 on Jun 3, 2025; 85 institutions reported holding it in 13F filings for Q1 2025, worth $17.1M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by bluebird bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for bluebird bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for bluebird bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Vittiglio JosephChief Business & Legal Officer0Jun 3, 20250
Leschly NickDirector0Jun 3, 20250
Vachon MarkDirector0Jun 3, 20250
Agwunobi John ODirector0Jun 3, 20250
Klima Thomas JSee Remarks0Jun 3, 20250
Cloonan MichaelDirector0Jun 3, 20250
Paulson Richard A.Director0Jun 3, 20250
Obenshain AndrewPresident and CEO0Jun 3, 20250
Leiderman ElisabethDirector0Jun 3, 20250
Sterling O. JamesChief Financial Officer0Jun 3, 20250
Tita-Reid NajohDirector0Jun 3, 20250
Jones-Burton CharlotteDirector0Jun 3, 20250
Colvin Richard AChief Medical Officer0Jun 3, 20250
Krawtschuk ChristopherChief Financial Officer45,474Mar 5, 20240
Cole JasonChief Strategy & Financial Off189,546Aug 23, 20220
Eggimann Anne-VirginieChief Regulatory Officer42,252Jul 14, 20220
Consylman GinaChief Financial Officer125,385Feb 3, 20220
Whitten JessicaChief Accounting Officer56,913Feb 3, 20220
Lynch DanielDirector7,959Nov 17, 20210
Dixon Wendy LDirector11,894Nov 17, 20210
Gregory Philip DChief Scientific Officer34,127Nov 17, 20210
Baird William D IIIChief Financial Officer22,797Nov 17, 20210
Glickman Sarah JSDirector0Nov 17, 20210
Sellers William R.Director3,601Nov 17, 20210
Ibrahim RamyDirector0Nov 17, 20210
Torres DeniceDirector2,726Nov 17, 20210
Maus Marcela V.Director0Nov 17, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 5, 2025 (view filing)Mar 32 daysColvin Richard AChief Medical OfficerSSale−584$3.92−$2.29K−7.1%7.61K after10b5-1
Mar 5, 2025 (view filing)Mar 32 daysKlima Thomas JSee RemarksSSale−500$3.92−$1.96K−6.0%7.88K after10b5-1
Mar 5, 2025 (view filing)Mar 32 daysObenshain AndrewPresident and CEOSSale−921$3.92−$3.61K−4.8%18.3K after10b5-1
Feb 5, 2025 (view filing)Feb 32 daysKlima Thomas JSee RemarksSSale−122$7.39−$901.58−1.4%8.38K after10b5-1
Feb 5, 2025 (view filing)Feb 32 daysColvin Richard AChief Medical OfficerSSale−64$7.39−$472.96−0.8%8.19K after10b5-1
Feb 5, 2025 (view filing)Feb 32 daysVittiglio JosephChief Business & Legal OfficerSSale−238$7.39−$1.76K−5.0%4.50K after10b5-1
Feb 5, 2025 (view filing)Feb 32 daysObenshain AndrewPresident and CEOSSale−86$7.39−$635.54−0.5%18.5K after10b5-1
Jan 8, 2025 (view filing)Jan 62 daysColvin Richard AChief Medical OfficerSSale−19$9.24−$175.56−0.2%8.26K after10b5-1
Jan 8, 2025 (view filing)Jan 62 daysObenshain AndrewPresident and CEOSSale−140$9.24−$1.29K−0.7%18.6K after10b5-1
Dec 12, 2024 (view filing)4:01 PM ETDec 102 daysObenshain AndrewPresident and CEOSSale−971$0.4173−$405.2−0.3%374.2K after10b5-1
Dec 12, 2024 (view filing)4:01 PM ETDec 102 daysColvin Richard AChief Medical OfficerSSale−2.82K$0.4173−$1.18K−1.7%165.5K after10b5-1
Oct 2, 2024 (view filing)Sep 302 daysKlima Thomas JSee RemarksSSale−1.01K$0.53−$533.18−0.6%170.0K after10b5-1
Oct 2, 2024 (view filing)Sep 302 daysObenshain AndrewPresident and CEOSSale−34.8K$0.53−$18.4K−8.5%375.2K after10b5-1
Jun 4, 2024 (view filing)Jun 31 dayKlima Thomas JSee RemarksSSale−3.83K$0.97−$3.72K−3.1%121.0K after10b5-1
Mar 5, 2024 (view filing)Mar 14 daysColvin Richard AChief Medical OfficerSSale−6.77K$1.53−$10.4K−5.4%118.4K after10b5-1
Mar 5, 2024 (view filing)Mar 41 dayObenshain AndrewPresident and CEOSSale−6.09K$1.53−$9.33K−2.1%280.0K after10b5-1
Mar 5, 2024 (view filing)Mar 41 dayKlima Thomas JSee RemarksSSale−4.57K$1.53−$7.00K−3.5%124.8K after10b5-1
Feb 6, 2024 (view filing)Feb 51 dayKlima Thomas JSee RemarksSSale−2.71K$0.90−$2.44K−2.1%129.4K after10b5-1
Feb 6, 2024 (view filing)Feb 51 dayVittiglio JosephChief Business & Legal OfficerSSale−5.22K$0.90−$4.70K−10.4%44.8K after10b5-1
Feb 6, 2024 (view filing)Feb 51 dayObenshain AndrewPresident and CEOSSale−1.88K$0.90−$1.69K−0.7%286.1K after10b5-1
Jan 9, 2024 (view filing)Jan 54 daysObenshain AndrewPresident and CEOSSale−3.16K$1.43−$4.52K−1.1%288.0K after10b5-1
Jan 9, 2024 (view filing)Jan 54 daysColvin Richard AChief Medical OfficerSSale−597$1.42−$847.74−0.5%125.1K after10b5-1
Dec 8, 2023 (view filing)Dec 62 daysKrawtschuk ChristopherChief Financial OfficerSSale−4.53K$4.52−$20.5K−9.1%45.5K after10b5-1
Nov 3, 2023 (view filing)Nov 3Same dayObenshain AndrewPresident and CEOSSale−807$3.17−$2.56K−0.3%291.1K after10b5-1
Nov 3, 2023 (view filing)Nov 21 dayColvin Richard AChief Medical OfficerSSale−2.34K$2.98−$6.98K−1.8%125.7K after10b5-1
Sep 6, 2023 (view filing)Sep 51 dayKlima Thomas JSee RemarksSSale−922$3.79−$3.49K−0.7%132.1K after10b5-1
Aug 10, 2023 (view filing)Aug 10Same dayObenshain AndrewPresident and CEOSSale−16.9K$3.54−$59.9K−5.5%291.9K after10b5-1
Jun 6, 2023 (view filing)Jun 24 daysKlima Thomas JSee RemarksSSale−4.13K$3.50−$14.5K−3.0%133.0K after
Mar 9, 2023 (view filing)Oct 17, 2022143 daysLateLeiderman ElisabethDirectorSSale−1.00K$6.46−$6.49K−8.1%11.5K after
Jan 13, 2023 (view filing)Jan 112 daysObenshain AndrewPresident and CEOSSale−3.18K$7.80−$24.8K−1.3%242.7K after
Jan 13, 2023 (view filing)Jan 112 daysColvin Richard AChief Medical OfficerSSale−557$7.80−$4.34K−0.7%74.2K after
Jan 13, 2023 (view filing)Jan 112 daysLeschly NickDirectorSSale−4.29K$7.80−$33.5K−1.5%280.1K after
Nov 8, 2022 (view filing)Nov 44 daysColvin Richard AChief Medical OfficerSSale−218$6.41−$1.40K−0.3%74.8K after
Nov 8, 2022 (view filing)Nov 44 daysObenshain AndrewPresident and CEOSSale−1.26K$6.41−$8.10K−0.5%245.9K after
Aug 23, 2022 (view filing)Aug 194 daysCole JasonChief Strategy & Financial OffSSale−14.2K$5.53−$78.5K−7.0%189.5K after
Aug 8, 2022 (view filing)Aug 44 daysObenshain AndrewPresident and CEOSSale−21.8K$4.39−$95.7K−8.1%247.1K after
Aug 8, 2022 (view filing)Aug 44 daysCole JasonChief Strategy & Financial OffSSale−7.45K$4.39−$32.7K−3.5%203.7K after
Jul 14, 2022 (view filing)Jul 122 daysEggimann Anne-VirginieChief Regulatory OfficerSSale−1.36K$4.95−$6.72K−3.1%42.3K after
Jun 7, 2022 (view filing)Jun 34 daysKlima Thomas JChief Commercial OfficerSSale−3.75K$3.07−$11.5K−5.0%71.4K after
Jan 12, 2022 (view filing)Jan 10-112 daysWhitten JessicaChief Accounting OfficerSSale−409$9.56−$3.91K−0.8%49.4K after2 lots
Jan 12, 2022 (view filing)Jan 10-112 daysCole JasonChief Operating andSSale−4.97K$9.56−$47.5K−2.6%186.2K after2 lots
Jan 12, 2022 (view filing)Jan 10-112 daysLeschly NickDirectorSSale−7.44K$9.56−$71.1K−2.6%281.3K after2 lots
Jan 12, 2022 (view filing)Jan 10-112 daysObenshain AndrewPresident and CEOSSale−7.72K$9.53−$73.6K−3.0%246.7K after3 lots
Jan 7, 2022 (view filing)Jan 52 daysWhitten JessicaChief Accounting OfficerSSale−2.98K$10.44−$31.2K−5.7%49.8K after
Dec 9, 2021 (view filing)Dec 72 daysObenshain AndrewPresident and CEOSSale−832$10.18−$8.47K−0.3%254.4K after